Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/8091
INCIDENCE, CLEARANCE, AND DISEASE PROGRESSION OF GENITAL HUMAN PAPILLOMAVIRUS INFECTION IN HETEROSEXUAL MEN.
Author
Affilliation
Associação Obras Sociais Irmã Dulce. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Salvador, BA, Brasil.
Center for Infection Research in Cancer. H. Lee Moffitt Cancer Center and Research Institute. Tampa, Florida.
University of California. Department of Medicine. San Francisco.
University Medical Center. National Public Health Institute. Morelos, Mexico.
Mount Sinai School of Medicine. New York, NY, USA.
Gynecologic Cancer Prevention Center Georgia Health Sciences University. Augusta.
Western Sydney Sexual Health Centre. University of Sydney. Australia.
University of Oslo. Olafia STI Clinic. Oslo University Hospital. Norway.
University of Virginia. Charlottesville.
Merck. North Wales. Pennsylvania.
Merck. North Wales. Pennsylvania.
Merck. North Wales. Pennsylvania.
Merck. North Wales. Pennsylvania.
Center for Infection Research in Cancer. H. Lee Moffitt Cancer Center and Research Institute. Tampa, Florida.
University of California. Department of Medicine. San Francisco.
University Medical Center. National Public Health Institute. Morelos, Mexico.
Mount Sinai School of Medicine. New York, NY, USA.
Gynecologic Cancer Prevention Center Georgia Health Sciences University. Augusta.
Western Sydney Sexual Health Centre. University of Sydney. Australia.
University of Oslo. Olafia STI Clinic. Oslo University Hospital. Norway.
University of Virginia. Charlottesville.
Merck. North Wales. Pennsylvania.
Merck. North Wales. Pennsylvania.
Merck. North Wales. Pennsylvania.
Merck. North Wales. Pennsylvania.
Abstract
BACKGROUND: In this analysis, we examine the incidence and clearance of external genital human papillomavirus (HPV) infection among heterosexual males aged 16-24 years. METHODS: A total of 1732 males aged 16-24 years old in the placebo arm of a quadrivalent HPV vaccine trial were included in this analysis. Participants were enrolled from 18 countries in Africa, the Asia-Pacific region, Europe, Latin America, and North America. Subjects underwent anogenital examinations and sampling of the penis, scrotum, and perineal/perianal regions. RESULTS: The incidence rate of any HPV DNA genotype 6, 11, 16, and/or 18 detection was 9.0 cases per 100 person-years. Rates of HPV DNA detection were highest in men from Africa. Median time to clearance of HPV genotypes 6, 11, 16, and 18 DNA was 6.1, 6.1, 7.7, and 6.2 months, respectively. Median time to clearance of persistently detected HPV 6, 11, 16, and 18 DNA was 6.7, 3.2, 9.2, and 4.7 months, respectively. CONCLUSION: The study results suggest that the acquisition of HPV 6, 11, 16, and/or 18 in males is common and that many of these so-called infections are subsequently cleared, similar to findings for women. Nevertheless, given the high rate of HPV detection among young men, HPV vaccination of males may reduce infection in men and reduce the overall burden of HPV-associated disease in the community.
Share